A new drug formulary that will allow cancer centers to access approved and investigational drugs for the use of preclinical and clinical studies in cancer treatment has been launched by the National Cancer Institute (NCI).
The new formulary is designed to help expedite availability of effective treatment options to patients with cancer. It is a public-private partnership between the NCI and the National Institutes of Health, along with private pharmaceutical and biotechnology companies.
“The NCI formulary will help researchers begin testing promising drug combinations more quickly, potentially helping patients much sooner,” NCI acting Director Dr. Douglas Lowy said. “Rather than spending time negotiating agreements, investigators will be able to focus on the important research that can ultimately lead to improved cancer care.”
A formulary is a list of approved drugs that offer the most value to patients and the treatment of their diseases.
New drug formulary creates greater access to cancer treatments
Alerts Sign-up